Does the media favor DYN or MDGL?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Dyne Therapeutics and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Dyne Therapeutics' score of 0.15 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or DYN?

In the previous week, Dyne Therapeutics had 7 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Dyne Therapeutics and 8 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Dyne Therapeutics' score of 0.15 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KRYS or DYN?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Krystal Biotech. MarketBeat recorded 15 mentions for Dyne Therapeutics and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Dyne Therapeutics' score of 0.15 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYMR or DYN?

In the previous week, Dyne Therapeutics had 11 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Dyne Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Dyne Therapeutics' score of 0.15 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARWR or DYN?

In the previous week, Dyne Therapeutics had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 15 mentions for Dyne Therapeutics and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat Dyne Therapeutics' score of 0.15 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyne Therapeutics (DYN) Competitors

$15.41 -0.41 (-2.60%)

As of 11:24 AM Eastern

Compare

DYN vs. MDGL, BMRN, KRYS, KYMR, and ARWR

Should you buy Dyne Therapeutics stock or one of its competitors? Dyne Therapeutics's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), BioMarin Pharmaceutical (BMRN), Krystal Biotech (KRYS), Kymera Therapeutics (KYMR), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Dyne Therapeutics (NASDAQ:DYN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Dyne Therapeutics had 13 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Dyne Therapeutics and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Dyne Therapeutics' score of 0.15 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dyne Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Madrigal Pharmaceuticals	$958.40M	11.93	-$288.28M	-$12.89	N/A

Dyne Therapeutics currently has a consensus price target of $33.07, suggesting a potential upside of 112.24%. Madrigal Pharmaceuticals has a consensus price target of $710.20, suggesting a potential upside of 43.53%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dyne Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Dyne Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Dyne Therapeutics and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Dyne Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Dyne Therapeutics	N/A	-64.30%	-50.33%

BioMarin Pharmaceutical presently has a consensus price target of $89.17, suggesting a potential upside of 53.43%. Dyne Therapeutics has a consensus price target of $33.07, suggesting a potential upside of 112.24%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Dyne Therapeutics had 7 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Dyne Therapeutics and 8 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Dyne Therapeutics' score of 0.15 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioMarin Pharmaceutical has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.49	$348.90M	$0.37	157.08
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Summary

BioMarin Pharmaceutical beats Dyne Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Dyne Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 13 more articles in the media than Krystal Biotech. MarketBeat recorded 15 mentions for Dyne Therapeutics and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Dyne Therapeutics' score of 0.15 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.90	$204.83M	$7.98	41.02
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech presently has a consensus price target of $377.20, suggesting a potential upside of 15.23%. Dyne Therapeutics has a consensus price target of $33.07, suggesting a potential upside of 112.24%. Given Dyne Therapeutics' higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Krystal Biotech beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Dyne Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 11 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Dyne Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Dyne Therapeutics' score of 0.15 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has higher revenue and earnings than Dyne Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	233.44	-$311.35M	-$3.24	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

96.7% of Dyne Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kymera Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $133.21, indicating a potential upside of 21.01%. Dyne Therapeutics has a consensus target price of $33.07, indicating a potential upside of 112.24%. Given Dyne Therapeutics' higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Kymera Therapeutics beats Dyne Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	11.11	-$1.63M	-$2.25	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 15 mentions for Dyne Therapeutics and 6 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat Dyne Therapeutics' score of 0.15 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals presently has a consensus price target of $98.31, indicating a potential upside of 50.29%. Dyne Therapeutics has a consensus price target of $33.07, indicating a potential upside of 112.24%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Dyne Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.92B	$3.93B	$7.22B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-4.69	13.45	272.64	25.80
Price / Sales	N/A	1,294.15	607.49	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	2.29	16.65	10.88	6.26
Net Income	-$446.21M	-$22.67M	$3.50B	$360.95M
7 Day Performance	-2.79%	-2.45%	-2.03%	-1.81%
1 Month Performance	-38.02%	-10.31%	-6.43%	-4.03%
1 Year Performance	24.16%	21.98%	8.95%	2.18%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.3668 of 5 stars	$15.41 -2.6%	$33.07 +114.6%	+26.6%	$2.88B	N/A	N/A	258	Analyst Forecast Analyst Revision
MDGL Madrigal Pharmaceuticals	3.0201 of 5 stars	$517.04 +0.1%	$710.20 +37.4%	+11.3%	$11.93B	$958.40M	N/A	915
BMRN BioMarin Pharmaceutical	4.3387 of 5 stars	$59.46 -1.3%	$89.17 +50.0%	+6.5%	$11.66B	$3.22B	160.70	3,221
KRYS Krystal Biotech	3.9817 of 5 stars	$337.08 -2.5%	$377.20 +11.9%	+81.1%	$10.24B	$389.13M	42.24	295
KYMR Kymera Therapeutics	1.8071 of 5 stars	$112.00 +0.0%	$133.21 +18.9%	+101.5%	$9.31B	$39.21M	N/A	273	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. MDGL, BMRN, KRYS, KYMR, and ARWR

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Dyne Therapeutics compare to Krystal Biotech?

Summary

How does Dyne Therapeutics compare to Kymera Therapeutics?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. MDGL, BMRN, KRYS, KYMR, and ARWR

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Does the media favor DYN or MDGL?

Do insiders and institutionals hold more shares of DYN or MDGL?

Which has more volatility & risk, DYN or MDGL?

Which has stronger earnings and valuation, DYN or MDGL?

Do analysts recommend DYN or MDGL?

Is DYN or MDGL more profitable?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Is BMRN or DYN more profitable?

Do analysts recommend BMRN or DYN?

Does the media refer more to BMRN or DYN?

Which has more volatility and risk, BMRN or DYN?

Do institutionals and insiders believe in BMRN or DYN?

Which has higher valuation & earnings, BMRN or DYN?

Summary

How does Dyne Therapeutics compare to Krystal Biotech?

Which has more volatility & risk, KRYS or DYN?

Is KRYS or DYN more profitable?

Does the media refer more to KRYS or DYN?

Which has stronger earnings & valuation, KRYS or DYN?

Do insiders & institutionals have more ownership in KRYS or DYN?

Do analysts prefer KRYS or DYN?

Summary

How does Dyne Therapeutics compare to Kymera Therapeutics?

Is KYMR or DYN more profitable?

Does the media refer more to KYMR or DYN?

Which has stronger valuation and earnings, KYMR or DYN?

Do institutionals and insiders have more ownership in KYMR or DYN?

Which has more volatility & risk, KYMR or DYN?

Do analysts rate KYMR or DYN?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Which has preferable valuation & earnings, ARWR or DYN?

Do institutionals & insiders believe in ARWR or DYN?

Which has more volatility & risk, ARWR or DYN?

Is ARWR or DYN more profitable?

Does the media prefer ARWR or DYN?

Do analysts prefer ARWR or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools